Gene expression in peripheral blood mononuclear cells from children with diabetes.

OBJECTIVE We hypothesized that type 1 diabetes (T1D) is accompanied by changes in gene expression in peripheral blood mononuclear cells due to dysregulation of adaptive and innate immunity, counterregulatory responses to immune dysregulation, insulin deficiency, and hyperglycemia. RESEARCH DESIGN AND METHODS Microarray analysis was performed on peripheral blood mononuclear cells from 43 patients with newly diagnosed T1D, 12 patients with newly diagnosed type 2 diabetes (T2D), and 24 healthy controls. One- and 4-month follow-up samples were obtained from 20 of the T1D patients. RESULTS Microarray analysis identified 282 genes differing in expression between newly diagnosed T1D patients and controls at a false discovery rate of 0.05. Changes in expression of IL1B, early growth response gene 3, and prostaglandin-endoperoxide synthase 2 resolved within 4 months of insulin therapy and were also observed in T2D, suggesting that they resulted from hyperglycemia. With use of a knowledge base, 81 of 282 genes could be placed within a network of interrelated genes with predicted functions including apoptosis and cell proliferation. IL1B and the MYC oncogene were the most highly connected genes in the network. IL1B was highly overexpressed in both T1D and T2D, whereas MYC was dysregulated only in T1D. CONCLUSION T1D and T2D likely share a final common pathway for beta-cell dysfunction that includes secretion of IL-1beta and prostaglandins by immune effector cells, exacerbating existing beta-cell dysfunction, and causing further hyperglycemia. The results identify several targets for disease-modifying therapy of diabetes and potential biomarkers for monitoring treatment efficacy.

[1]  N. Simpson,et al.  A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. , 1989, The New England journal of medicine.

[2]  P. Linsley,et al.  Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Natarajan,et al.  Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. , 2004, Diabetes.

[4]  T. Mandrup-Poulsen.  beta-cell apoptosis: stimuli and signaling. , 2001, Diabetes.

[5]  C. Kahn,et al.  Analysis of gene expression in pathophysiological states: balancing false discovery and false negative rates. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  M. Atkinson,et al.  The pathogenesis of insulin-dependent diabetes mellitus. , 1994, The New England journal of medicine.

[7]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[8]  R. Williamson,et al.  On the Treatment of Glycosuria and Diabetes Mellitus with Sodium Salicylate , 1901, British medical journal.

[9]  D. Wedekind,et al.  Immune cell infiltration, cytokine expression, and beta-cell apoptosis during the development of type 1 diabetes in the spontaneously diabetic LEW.1AR1/Ztm-iddm rat. , 2005, Diabetes.

[10]  John D. Storey,et al.  A network-based analysis of systemic inflammation in humans , 2005, Nature.

[11]  J. Banchereau,et al.  Gene expression patterns in blood leukocytes discriminate patients with acute infections. , 2007, Blood.

[12]  S. Sicherer,et al.  Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition , 2007, Pediatrics.

[13]  M. Atkinson,et al.  Aberrant monocyte prostaglandin synthase 2 (PGS2) expression in type 1 diabetes before and after disease onset , 2003, Pediatric diabetes.

[14]  Woncheol Jang,et al.  How accurately can we control the FDR in analyzing microarray data? , 2006, Bioinform..

[15]  Daniel R. Richards,et al.  Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways , 2006, Proceedings of the National Academy of Sciences.

[16]  Kathrin Maedler,et al.  Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes , 2003, Journal of Molecular Medicine.

[17]  R. Unger,et al.  Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity. , 1997, The Journal of clinical investigation.

[18]  M. Bugliani,et al.  Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? , 2005, Diabetes.

[19]  Thomas Mandrup-Poulsen Pancreatic.  - Cell Apoptosis Stimuli and Signaling , 2001 .

[20]  P. White,et al.  Improving management of diabetic ketoacidosis in children. , 2001, Pediatrics.

[21]  M. Banerji,et al.  Autoantibodies in children with type 2 diabetes mellitus. , 2002, Journal of pediatric endocrinology & metabolism : JPEM.

[22]  D. Hafler,et al.  Loss of IL-4 Secretion from Human Type 1a Diabetic Pancreatic Draining Lymph Node NKT Cells , 2005, The Journal of Immunology.

[23]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[24]  Ivan C Gerling,et al.  New Data Analysis and Mining Approaches Identify Unique Proteome and Transcriptome Markers of Susceptibility to Autoimmune Diabetes* , 2006, Molecular & Cellular Proteomics.

[25]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[26]  P. Ott,et al.  CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. , 2004, Journal of immunological methods.

[27]  T. Hughes,et al.  Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products , 2004, Diabetologia.

[28]  R. Flavell,et al.  The temporal importance of TNFalpha expression in the development of diabetes. , 2000, Immunity.

[29]  R. Palmiter,et al.  Overexpression of c-Myc in beta-cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes. , 2002, Diabetes.

[30]  Yoshiaki Tanaka,et al.  Nesidioblastosis treated successfully by 85% pancreatectomy. , 2004, The Kurume Medical Journal.

[31]  A. Larsson,et al.  Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. , 2005, Diabetes care.

[32]  Yoav Benjamini,et al.  Identifying differentially expressed genes using false discovery rate controlling procedures , 2003, Bioinform..

[33]  R. Horuk,et al.  The clinical potential of chemokine receptor antagonists. , 2005, Pharmacology & therapeutics.

[34]  T. Saruta,et al.  Glutamic acid decarboxylase65 (GAD65) antibodies and insulin auto-antibodies in Japanese patients with non-insulin-dependent diabetes mellitus. , 1997, Endocrine journal.

[35]  Daniel R. Richards,et al.  Corrigendum: A network-based analysis of systemic inflammation in humans , 2005, Nature.

[36]  E. Bonifacio,et al.  Comparison of Insulin Autoantibodies in Diabetes-Related and Healthy Populations by Precise Displacement ELISA , 1989, Diabetes.

[37]  Christophe Benoist,et al.  β-Cell death during progression to diabetes , 2001, Nature.

[38]  L. Lanting,et al.  Regulation of Cyclooxygenase-2 Expression in Monocytes by Ligation of the Receptor for Advanced Glycation End Products* , 2003, Journal of Biological Chemistry.